Tiotropium for asthma: A summary of current guidelines and a case study.
J Am Assoc Nurse Pract
; 30(8): 460-463, 2018 Aug.
Article
en En
| MEDLINE
| ID: mdl-30085989
ABSTRACT
BACKGROUND AND PURPOSE:
The long-acting muscarinic antagonist tiotropium received an indication for the treatment of asthma from the FDA in 2015.METHODS:
This paper summarizes much of the published findings on tiotropium and asthma and explores the heterogeneity of the asthma population vis-à-vis recent changes in guidelines for management of COPD. The accompanying case study provides an illustration of how tiotropium might be added to a patient's regimen appropriately. CONCLUSIONS AND IMPLICATIONS FOR PRACTICE Tiotropium has been shown in many studies to be beneficial to patients with asthma as an add-on medication. It should be considered as an agent by the clinician managing patients with both allergic and non-allergic asthma.
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Asma
/
Guías como Asunto
/
Bromuro de Tiotropio
Tipo de estudio:
Etiology_studies
/
Guideline
Idioma:
En
Revista:
J Am Assoc Nurse Pract
Año:
2018
Tipo del documento:
Article